Thank you.
I have limited time left. Psychedelics Canada is asking for three key things. They want more federal government research into this by the Canadian Institutes for Health Research; they want clear, effective and evidence-based regulations; and they want a pharmacist compounding psychedelic substances under Health Canada's special access program.
Can you add a little bit more to that and put it in the context of the barriers you have faced under current regulations? What kind of recommendations would you like to see this committee make in its final report so that we are making sure that end-of-life care truly is a patient-centred approach?